Peter Andersen

Peter Høngaard Andersen was the founder of ACADIA Pharmaceuticals A, founded in 1997, where the title held was Vice President from 1997 to 1999.
Dr. Andersen was also the founder of Zealand Pharma A,Glycom A,EpiTherapeutics ApS,Prexton Therapeutics SA,InnovationsFonden..
Dr. Andersen previously served as Chairman-Research Directors Group at the European Federation of Pharmaceutical Industries & Assns since 2014.
The current roles also include Chairman at Immunovia AB since 2023, Chairman at Biotech Research & Innovation Centre, Director at Ossianix, Inc., Operating Partner at Forbion Capital Partners Management Holding BV since 2022, Member at Collegium Internationale Neuro-Psychopharmacologicum, and Member at Scandinavian Society for Psychopharmacology.
Former positions include Chairman at Lundbeck Research USA, Inc., Vice-Chairman at Scandion Oncology A in 2019, Chairman at Edvince AB, Director-Supervisory Board at to-BBB Holding BV, Director & Executive Vice President-Research at Lundbeck Pharma A from 2011 to 2014, Director at Serendex Pharmaceuticals A, Director at Imara, Inc., Director at Monsenso A, Project Manager-Metabolic Disease at Novo Nordisk A from 1984 to 1987, SVP-External Scientific Relations & Patents at H.
Lundbeck A, Member-Supervisory Board at to-BBB technologies BV, and Venture Partner at Ysios Capital Partners SGEIC SA from 2020 to 2023.
Education includes graduate and doctorate degrees from the University of Copenhagen.